British drugmaker Shire reassured investors that it was on target to meet 2013 earnings expectations and said it was boosting its genetic drugs line with a new acquisition.The company, which has expanded by acquiring late-stage or already marketed drugs in niche areas, had a weak third quarter, missing market expectations as it faced increased generic competition for its hyperactivity drug.However, outgoing CEO Angus Russell will tell investors at a healthcare conference in San Francisco that the company "is now increasingly confident of meeting current consensus earnings expectations for 2013", Shire said in a statement on Tuesday.Analysts forecast earnings per share of $2.20 in 2013, according to Thomson Reuters I/B/E/S estimates.
Thomson Reuters Corporation (Thomson Reuters) is a provider of information for the world?s businesses and professionals. Shares of TRI traded higher by 0.17% or $0.05/share to $29.34. In the past year, the shares have traded as low as $26.20 and as high as $30.66. On average, 746021 shares of TRI exchange hands on a given day and today's volume is recorded at 245833.
Thomson Reuters Corporation (Thomson Reuters) is a provider of information for the world?s businesses and professionals. Shares of TRI traded higher by 0.42% or $0.12/share to $28.96. In the past year, the shares have traded as low as $26.47 and as high as $30.25. On average, 891811 shares of TRI.TO exchange hands on a given day and today's volume is recorded at 206049.
Source
